The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
Gerald Steven Falchook
Research Funding - Circadian
Jayesh Desai
Consultant or Advisory Role - Vegenics
Ian M. Leitch
Employment or Leadership Position - Vegenics
Stock Ownership - Circadian
Jonathan Wade Goldman
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Siqing Fu
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Megan Baldwin
Employment or Leadership Position - Vegenics
Stock Ownership - Circadian
Lee S. Rosen
Research Funding - Vegenics